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Abstract A novel receptor for oxidized low-density lipoprotein
(OxLDL), lectin-like OxLDL receptor (LOX-1), was cloned
from endothelial cells. Since OxLDL is taken up by vascular
smooth muscle cells (VSMC) in atheroma, we analyzed the
inducible expression of LOX-1 in VSMC in the present study.
Incubation of cultured bovine VSMC with lysophosphatidylcho-
line (LPC), an atherogenic component of OxLDL, increased the
level of mRNA for LOX-1 in a dose- and time-dependent
manner. Since LPC did not significantly change the half-life of
LOX-1 mRNA, the induction seemed to occur at the transcrip-
tional level. The induction accompanied an increase in the protein
level of LOX-1 and activity of OxLDL uptake. Blocking
antibody against LOX-1 significantly suppressed the enhanced
uptake of OxLDL. Thus, LOX-1 is a major receptor for
OxLDL in VSMC as in endothelial cells. The enhanced
expression of LOX-1 by LPC suggests that OxLDL and LPC
would progressively change the function of VSMC and accelerate
atherogenesis in vivo.
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1. Introduction
Oxidized low-density lipoprotein (OxLDL) is believed to be
a key atherogenic component which induces endothelial dys-
function and accumulation of foam cells [1]. A number of
‘scavenger receptors’ characterized by binding to OxLDL
have been identi¢ed [1]. Among them, lectin-like OxLDL re-
ceptor-1 (LOX-1) identi¢ed in our laboratory is uniquely ex-
pressed in the endothelial cells of large arteries [2]. LOX-1 is a
type II membrane protein with a C-type lectin-like structure at
the C-terminus. Besides OxLDL, LOX-1 binds aged/apoptotic
cells, suggesting potential physiological functions [3]. The ex-
pression of LOX-1 in endothelial cells in vitro and in vivo is
highly regulated. LOX-1 expression is induced by TNF-K,
phorbol ester, shear stress, LPS, angiotensin II and OxLDL
in cultured endothelial cells, and by hypertension in vivo [4^
10]. Recently, LOX-1 was found to be expressed in macro-
phages and vascular smooth muscle cells (VSMC) in atherom-
atous intima and culture [5,11^13]. Since macrophages and
smooth muscle cells transform into foam cells in atheroma,
a potential role for LOX-1 in foam cell formation has been
suggested.
Lysophosphatidylcholine (LPC) is a well characterized athe-
rogenic component of OxLDL, being generated during oxida-
tion of LDL and accumulated in atheroma. LPC causes en-
dothelial dysfunction characterized by impairment of release
of nitric oxide, expression of adhesion molecules, and expres-
sion of growth factors [14^16]. LPC acts on VSMC as well,
and induces proliferation and the release of ¢broblast growth
factor-2 [17,18].
To address the signi¢cance of the expression of LOX-1 in
VSMC in atheroma, we explored whether LOX-1 constitutes a
signi¢cant part of OxLDL receptors in LPC-stimulated
VSMC.
2. Materials and methods
2.1. Cells
Bovine thoracic aortas were obtained from a local slaughterhouse.
Endothelial cells were removed by scraping with a knife the internal
surface of aortas. Small pieces (V5 mmU5 mm) of the medial layer
cut from the aorta were explanted on a culture dish, and were then
maintained for a week in Dulbecco’s modi¢ed Eagle’s medium
(DMEM, Nissui, Japan) containing 10% (v/v) fetal calf serum (JRH
Bioscience, Lenexa, KS, USA), ampicillin (50 Wg/ml), streptomycin
(50 Wg/ml) and amphotericin B (0.25 Wg/ml) under a humidi¢ed at-
mosphere of 5% CO2/95% air at 37‡C [2]. Migrated smooth muscle
cells from the explants were used as VSMC and maintained with the
above medium.
2.2. Preparation of lipoproteins
LDL (density: 1.019^1.063 g/ml) was isolated by sequential ultra-
centrifugation from human plasma. LDL was oxidatively modi¢ed by
exposure to 7.5 WM CuSO4 in phosphate-bu¡ered saline (PBS) with-
out calcium and magnesium for about 20 h at 37‡C as described [2].
Oxidation was monitored by measuring the amount of thiobarbituric
acid-reactive substances. The degree of the oxidation was approxi-
mately 10 nmol malondialdehyde equivalent/mg protein. Agarose gel
electrophoresis showed increased electrophoretic mobility and mini-
mal aggregation of OxLDL particles. Labeling of LDL with 1,1P-
dioctadecyl-3,3,3P,3P-tetramethylindocarbocyanine perchlorate (DiI)
(Molecular Probes, Eugene, OR, USA) was performed as previously
described [2].
2.3. Treatment of VSMC with LPC
Stearoyl LPC was obtained from Sigma and dissolved in DMEM
containing 0.3% bovine serum albumin (BSA). VSMC were cultured
in DMEM containing 0.3% BSA for 24 h before treatment with LPC.
The viability of cells was con¢rmed by the trypan blue exclusion assay
and by the measurement of the activity of lactate dehydrogenase as
described [19].
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2.4. Northern blotting
Total RNA was isolated from VSMC by the acid guanidium-phe-
nol-chloroform method and electrophoresed through 1.1% agarose
gels containing formaldehyde. RNA was then transferred to nylon
membranes. The membranes were hybridized with a cDNA fragment
of bovine LOX-1 or human glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) as described previously [2]. To determine the half-life
of LOX-1 mRNA, serum-starved VSMC were treated for di¡erent
periods with actinomycin D (5 Wg/ml) in the absence or presence of
LPC. The logarithm of percent RNA remaining was plotted against
the time after the actinomycin D addition, and the half-life was calcu-
lated by linear regression analysis.
2.5. Uptake of DiI-OxLDL by VSMC
VSMC were cultured on a glass-bottom culture dish (Meridien,
Ashland, MA, USA). The cells were incubated with LPC for 18 h,
and then 5 Wg/ml DiI-OxLDL was added to the medium and in-
cubation continued for 2 h under absence or presence of anti-LOX-
1 antibody, JTX20. The cells were ¢xed with 4% formaldehyde and
0.2% glutaraldehyde in PBS and examined by £uorescence micros-
copy.
2.6. Statistics
To test for the di¡erences between experimental groups, Student’s t
test (unpaired and two-tailed) was performed.
3. Results
Treatment of cultured bovine VSMC with LPC for 12 h
increased the level of LOX-1 mRNA at as low as 3 WM and
dose-dependently increased the mRNA level within a range of
0^100 WM, whereas the mRNA level of GAPDH was not
a¡ected by LPC (Fig. 1). Similarly, Western blot analysis
showed that this induction was accompanied by an increase
in the protein level of LOX-1, detecting LOX-1 as a 50 kDa
protein (data not shown). Time course analysis of the induc-
tion showed a signi¢cant increase of the mRNA level for
LOX-1 within 3 h. The induction had a peak at 12 h and
Fig. 1. Dose-dependent induction of LOX-1 mRNA by LPC. Total
RNA was prepared from VSMC after treatment with the indicated
concentrations of stearoyl LPC in DMEM containing 0.3% BSA for
12 h. RNA (3 Wg/lane) was separated by electrophoresis and hybrid-
ized with bovine LOX-1 cDNA probe. Hybridization of the
GAPDH cDNA probe to the same membrane was done to show
the uniformity in quantity of RNA among samples. The upper pan-
el shows a representative of three reproducible results. The lower
panel shows a semi-quantitative analysis of the results. Data are the
mean þ S.E.M.
Fig. 2. Time course of LOX-1 mRNA induction by LPC. VSMC
were treated with 100 WM stearoyl LPC in DMEM with 0.3% BSA
for the period indicated. The amount of LOX-1 mRNA was ana-
lyzed as in Fig. 1.
Fig. 3. VSMC were treated with 100 WM stearoyl LPC in DMEM
with 0.3% BSA for 12 h under the presence or absence of 50 WM
H-7. The amount of LOX-1 mRNA was analyzed as in Fig. 1.
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decreased at 18 h although the level remained higher than that
at time 0 (Fig. 2). Protein levels of LOX-1 also showed a
signi¢cant increase within 6 h and peaked at 18 h, several
hours after the mRNA induction (data not shown). Since
LOX-1 has a cluster of unstabilizing signals in the 3P-untrans-
lated region of mRNA, the e¡ect of LPC on the half-life of
mRNA for LOX-1 in VSMC was examined. The half-life of
LOX-1 mRNA in the presence and absence of LPC was
4.4 þ 1.3 and 4.3 þ 1.2 h, respectively, showing no signi¢cant
di¡erence. This result suggests that the induction by LPC
occurs at the transcriptional level. Furthermore, treatment
of VSMC with H-7, an inhibitor for protein kinase C, signi¢-
cantly suppressed the induction of LOX-1 mRNA, suggesting
protein kinase C might be involved in the signal transduction
triggered by LPC (Fig. 3). Then, we con¢rmed that the in-
duction of LOX-1 by LPC was accompanied by activity of
VSMC to take up OxLDL. The LPC-treated VSMC showed
intense £uorescence of DiI as a result of uptake of OxLDL in
a dose-dependent manner (Fig. 4A^C). The enhanced uptake
was signi¢cantly hampered by the introduction of anti-LOX-1
neutralizing antibody into the medium for taking up OxLDL
(Fig. 4D^F), indicating most of the induced activity can be
ascribed to LOX-1.
4. Discussion
Functions of cells that constitute atherosclerotic blood ves-
sels are modi¢ed by the factors present in atheroma. Some of
these factors are released by the cells, others are derived from
plasma. The former include TNF-K, TGF-L, IL-8, G-CSF
etc., the latter, OxLDL and its lipid constituents. Among
them, LPC is the best-characterized atherogenic molecule. It
constitutes about 40% of the total lipid component of OxLDL
and is accumulated in atherosclerotic tissue at about 1 mM. In
endothelial cells, LPC impairs the release of nitric oxide and
promotes the expression of leukocyte adhesion molecules, leu-
kocyte chemotactic factors and growth factors. In VSMC,
LPC works as a growth factor and chemoattractant. Here,
we showed that LPC induces expression of LOX-1 in
VSMC. This suggests that LPC strengthens the e¡ect of
OxLDL on VSMC and further promotes functional change
of VSMC. There are reports that lipid components other than
LPC also mediate the action of OxLDL. 25-Hydroxycholes-
terol was reported to mediate apoptosis of endothelial cells
and 13- and 15-hydroxyoctadecadienoic acid, agonists for per-
oxysome proliferator-activated receptor-Q, to mediate the in-
duction of CD36 expression in macrophage [20,21]. Although
we did not examine the e¡ect of these substances in the
present study, it is possible that they change the expression
level of LOX-1 together with LPC as components of OxLDL.
One study described that the phorbol ester induced the ex-
pression of another type of OxLDL receptor, class A scav-
enger receptor, in cultured rabbit VSMC [22]. Despite the
possible expression of other types of OxLDL receptors, the
neutralizing antibody for LOX-1 signi¢cantly inhibited the
LPC-enhanced uptake of OxLDL in VSMC in the present
study. This result indicates that the part of the activity to
uptake OxLDL can be ascribed to LOX-1 at least in some
conditions as demonstrated in endothelial cells. Various ef-
fects of OxLDL on VSMC have been reported. OxLDL alters
the expression of the proteins which constitute the contractile
machinery of cultured mouse and rat aortic smooth muscle
cells, i.e. it decreases the expression of K-actin, smooth muscle
myosin heavy chain-1 and calponin [23]. OxLDL is chemo-
tactic for cultured bovine smooth muscle cells [24]. It induces
the proliferation of cultured smooth muscle cells by stimulat-
ing the release of ¢broblast growth factor-2 [18]. OxLDL
stimulates synthesis of collagen from porcine cultured aortic
smooth muscle cells [25]. It stimulates the extracellular matrix
and induces apoptosis under some conditions in cultured hu-
man coronary artery smooth muscle cells [26]. These in vitro
e¡ects of OxLDL on VSMC well illustrate the in vivo behav-
ior of VSMC in atheroma, speci¢cally, the change from a
contractile to synthetic phenotype, migration from media to
intima, proliferation in intima, synthesis of matrix proteins,
and eventual death in acute coronary syndrome. VSMC are
also well-known to participate in the formation of foam cells
as well as macrophages, probably taking up OxLDL in athe-
roma [1]. LOX-1 expressed in VSMC as a major part of the
OxLDL receptor may mediate these various actions of
OxLDL on VSMC, and blockade of the action of LOX-1
might delay the progression of atherosclerosis and related
diseases.
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Fig. 4. Uptake of DiI-OxLDL by LPC-treated VSMC. VSMC were
treated with 0 (A, D), 30 (B, E) or 100 WM (C, F) stearoyl LPC for
18 h in the absence (A^C) or presence (D^F) of anti-LOX-1 anti-
body, then incubated with 5 Wg/ml DiI-OxLDL for 2 h. The upper
panel shows a representative of three reproducible results. The lower
panel shows a semi-quantitative analysis of the results. Data are the
mean þ S.E.M.
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